ClinicalTrials.gg
Not yet recruitingNCT07553559INTERLACEUpdated Nov 19, 2026

Evaluating an Artificial Intelligence-Based Diagnostic Support Tool for Older Adults in Primary Care

An interventional study of Artificial intelligence-based clinical decision support tool for diagnostic support in Diagnostic Support, sponsored by University of Pennsylvania. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

Older adults commonly experience diagnostic errors that may lead to direct harms and increased healthcare costs. Older adults are especially at risk because of higher rates of comorbidity burden, medical complexity, frailty, and cognitive impairment. An artificial intelligence (AI) clinical decision support system (CDSS) offers a promising approach to promote diagnostic excellence for older adults.

The purpose of this study is to assess the acceptability and feasibility of a new AI CDSS for older adults in primary care. The goal of this AI CDSS is to provide diagnostic support during primary care visits (i.e., help make timely and accurate diagnoses) and support communication amongst patients, doctors, and caregivers about the patient's health.

In this study, participants will use the AI CDSS in a primary care visit and review its suggestions for diagnoses and tests. Afterwards, they will complete a feedback survey and interview where they share their thoughts about and experience using the AI CDSS.

02

Conditions studied

  • Diagnostic Support
03

In context

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 231 are open to participants now.

Of its 159 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinicians

  1. Work in the University of Pennsylvania Health System
  2. Work in a primary care setting (i.e., Internal Medicine, Geriatric Medicine, Family Medicine, and Penn Primary Care)
  3. Actively treat adult patients who are 65 years old or older

Patients

  1. 65 years of age or older
  2. Have an upcoming encounter with a participating primary care clinician
  3. Indicate a new or worsening health concern that they wish to discuss at the upcoming encounter

Caregivers

  1. 18 years old or older
  2. Accompanying the participating patient during the encounter with the AI CDSS
  3. Identified by the patient as a caregiver

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Under the age of 18 years old
  2. Unable to provide in the opinion of the investigator
  3. Has a "Research Do Not Contact" status in the electronic health record
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Use of INTERLACE tool in primary care visit

    All participants will be asked to use INTERLACE in their primary care visit. The tool will be presented on an handheld electronic device and may be used by patients, caregivers, and primary clinicians at each visit. First, the patient will input their current symptoms into INTERLACE. Then, using these symptoms, latest vital signs, and the patient's medical history, INTERLACE will make suggestions for diagnoses and tests. Patients, caregivers, and clinicians can view and discuss these suggestions together to arrive at a potential diagnosis.

    Other: Artificial intelligence-based clinical decision support tool for diagnostic support

Interventions

  • OtherArtificial intelligence-based clinical decision support tool for diagnostic support

    INTERLACE is an artificial intelligence-based clinical decision support tool. It uses a patient's medical history, vital signs, and current symptoms to make suggestions for diagnoses and tests. These suggestions can be considered and discussed amongst patients, caregivers, and clinicians during primary care visits to help find a good diagnosis for the patient's symptoms.

06

What researchers measure

Primary outcomes

  1. Feasibility of embedding the AI CDSS into a primary care visit

    Participants will complete a Feasibility of Intervention Measure (FIM) via feedback survey following the primary care visit. Responses are measured on a 5-point Likert scale.

    Time frame: From enrollment to the end of the study interview, up to two weeks

  2. Feasibility of embedding the AI CDSS into a primary care visit

    Feasibility will also be assessed through brief survey questions asking whether participants experienced any barriers to using INTERLACE, whether it was useful during the visit, and how long it was used (all measured on a 7-point Likert scale), as well as open-ended questions in a semi-structured interview.

    Time frame: From enrollment until the end of the study interview, up to two weeks

  3. Acceptability of embedding the AI CDSS into a primary care visit

    Participants will complete the Acceptability of Intervention Measure (AIM) via feedback survey after the primary care visit. Responses to the AIM are measured on a 5-point Likert scale.

    Time frame: From enrollment until the end of the study interview, up to two weeks

  4. Acceptability of embedding the AI CDSS into a primary care visit

    Participants will also complete a modified version of the Technology Acceptance model (TAM). Responses to the TAM are measured on a 7-point Likert scale.

    Time frame: From enrollment until the end of the study interview, up to two weeks

  5. Acceptability of embedding the AI CDSS into a primary care visit

    Participants will complete a Net Promoter Score assessing the likelihood that they would recommend the AI CDSS to others at the end of the survey. This will be measured on a 10-point scale.

    Time frame: From enrollment until the end of the study interview, up to two weeks

  6. Acceptability of embedding the AI CDSS into a primary care visit

    Acceptability will also be assessed through brief survey questions assessing whether INTERLACE caused distress (measured on a 7 point Likert scale), as well as open-ended questions in a semi-structured interview.

    Time frame: From enrollment until the end of the study interview, up to two weeks

07

Study locations

1 site
  • University of Pennsylvania
    Philadephia, Pennsylvania 19104, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Oct 2026 → Jan 2027, primary completion Jan 2027 → Jun 2027 and completion Jan 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 28, 2026
StartEst.
Jan 2027was Oct 2026
Primary completionEst.
Jun 2027was Jan 2027
CompletionEst.
Jun 2027was Jan 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jan 2027
Nov 19, 2026
Primary completion
Jan 2027→Jun 2027
Nov 19, 2026
Study completion
Jan 2027→Jun 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Oct 2026→Jan 2027
    Primary completion Jan 2027→Jun 2027
    Study completion Jan 2027→Jun 2027
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07553559
Collaborators
Penn Artificial Intelligence and Technology (PennAITech) Collaboratory for Healthy Aging, National Academy of Medicine (NAM)
Responsible party
Gary Weissman (Assistant Professor of Medicine and Informatics, University of Pennsylvania) — Principal investigator
First posted
Apr 28, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Alyssa M Sliwa, BA
Contact
alyssa.sliwa@pennmedicine.upenn.edu
215-746-3080
Nicholas Bishop, BA
Contact
nicholas.bishop@pennmedicine.upenn.edu
Gary E Weissman, MD, MSPH
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion